Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer
The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed abiraterone.
Metastatic Castration-resistant Prostate Cancer
DRUG: SX-682|DRUG: Enzalutamide
Clinical Benefit, A composite endpoint defined as 1) iRECIST iCR or iPR, 2) PSA50 or 3) stable disease by iRECIST and PCWG3 bone scan criteria for at least 6 months, Ten 21-day treatment cycles
Adverse Events, Number of participants experiencing adverse events (AEs), Ten 21-day treatment cycles|Progression-free survival, Time from the date study treatment starts to the earliest progression event, Ten 21-day treatment cycles|Overall survival, The time from the start of study treatment until death due to any cause, Up to 3 years
The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed abiraterone.